Volume | 3,898,760 |
|
|||||
News | - | ||||||
Day High | 133.7484 | Low High |
|||||
Day Low | 131.07 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Novo Nordisk | NVO | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
131.57 | 131.07 | 133.7484 | 132.89 | 132.37 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
66,580 | 3,898,760 | $ 132.66 | $ 517,206,032 | - | 70.895 - 138.28 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:52 | 1 | $ 132.92 | USD |
Novo Nordisk (NVO) Options Flow Summary
Novo Nordisk Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
596.04B | 4.51B | - | 232.26B | 83.68B | 18.56 | 7.12 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Novo Nordisk News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NVO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 133.38 | 135.92 | 130.75 | 133.38 | 5,199,221 | -0.06 | -0.04% |
1 Month | 124.62 | 138.28 | 118.3003 | 128.75 | 6,150,850 | 8.70 | 6.98% |
3 Months | 102.74 | 138.28 | 101.71 | 118.83 | 5,182,036 | 30.58 | 29.76% |
6 Months | 92.645 | 138.28 | 86.96 | 108.00 | 4,836,326 | 40.68 | 43.90% |
1 Year | 71.07 | 138.28 | 70.895 | 102.61 | 3,215,881 | 62.25 | 87.59% |
3 Years | 35.375 | 138.28 | 33.295 | 80.68 | 1,917,888 | 97.95 | 276.88% |
5 Years | 25.685 | 138.28 | 23.00 | 63.71 | 1,717,407 | 107.64 | 419.06% |
Novo Nordisk Description
Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders. |